Kübra ÖZKAYA, Musa ALTUN, Rejin KEBUDİ, Sema BÜYÜKKAPU BAY

Second Primary Malignancies in Pediatric and Adolescent Nasopharyngeal Carcinoma Survivors: Experience of a Single-center

OBJECTIVE The aim of this study is to investigate the incidence and clinicopathologic characteristics of second primary malignancies (SPMs) in pediatric and adolescent nasopharyngeal carcinoma (NPC) survivors from the point of patients’ age, emergence time, location and histopathology. METHODS Medical reports of pediatric NPC patients (patients at or under the age of 19) treated between 1990 and 2017 and followed till the end 2020 were reviewed. SPMs are classified depending on the organ, histopathology, location (whether in or out of the radiation field). Additionally time period between NPC treatment and diagnosis of second primaries are recorded. RESULTS The median age of the 108 patients at diagnosis was 15 years (5-19 years). The male-to-female ratio was 2.1. The median follow-up was 118 months (3-332 months). Eight patients developed 9 second malignancies (one patient with two SPMs). Eight of SPMs were in the radiation field. SPMs developed at a median of 15 years (5-26 years) after the conclusion of the primary treatment. Among patients, whose malignancy developed in the irradiation field 6 were treated primarily with complete surgical resection and 3 of them died because of SPM. CONCLUSION Incidences of SPMs have been increasing in parallel with the increase in life expectancy of pediatric and adolescent NPC survivors. Due to relatively high numbers of SPMs, pediatric/adult nasopharyngeal cancer survivors should be followed regularly not only for recurrences and long term morbidities but also for second malignancies which may be treated with curative surgeries and additional treatments when diagnosed early. The patient follow-up should continue and patients should be evaluated comprehensively, taking into account cancers outside the irradiation field. Since the most of the SPMs develops in the irradiation field, prospective clinical studies investigating dose reduction in the treatment of pediatric NPC should be considered and evaluated with further prospective trials.

PDF

___

1. O’Leary M, Krailo M, Anderson JR, Reaman GH; Children’s Oncology Group. Progress in childhood cancer: 50 years of research collaboration, a report from the Children’s Oncology Group. Semin Oncol 2008;35(5):484–93.
2. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol 2012;30(30):3734–45.
3. Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 2016;122()19:3075–86.
4. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001;93(8):618–29.
5. Ayan I, Altun M. Nasopharyngeal carcinoma in children: Retrospective review of 50 patients. Int J Radiat Oncol Biol Phys 1996;35(3):485–492.
6. Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis. Lancet Oncol 2015;16(6):645–55.
7. Chen YP, Ismaila N, Chua ML, Colevas AD, Haddad R, Huang SH, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol 2021;39(7):840–59.
8. Jensen JS, Grønhøj C, Kjær EK, Charabi BW, von Buchwald C, Hjuler T. Second primary cancers in pediatric head and neck cancer survivors in Denmark during 1980-2014: A nationwide study. Int J Pediatr Otorhinolaryngol 2019;127:109648.
9. Ben-Ami T, Ash S, Ben-Harosh M, Gavriel H, Weintraub M, Revel-Vilk S, et al. Nasopharyngeal carcinoma in children and young adults-Beyond 5-year survival. Pediatr Blood Cancer 2020;67(9):e28494.
10. Cheuk DK, Billups CA, Martin MG, Roland CR, Ribeiro RC, Krasin MJ, et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer 2011;117(1):197–206.
11. Jouin A, Helfre S, Bolle S, Claude L, Laprie A, Bogart E, et al. Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: The French experience. Strahlenther Onkol 2019;195(6):504–16.
12. Lu S, Chang H, Sun X, Zhen Z, Sun F, Zhu J, et al. Long-term outcomes of nasopharyngeal carcinoma in 148 children and adolescents. Medicine (Baltimore) 2016;95(17):e3445.
13. Kontny U, Franzen S, Behrends U, Bührlen M, Christiansen H, Delecluse H, et al. Diagnosis and treatment of nasopharyngeal carcinoma in children and adolescents recommendations of the GPOH-NPC study group. Klin Padiatr 2016;228(3):105–12.
14. Cağlar K, Varan A, Akyüz C, Selek U, Kutluk T, Yalçin B, et al. Second neoplasms in pediatric patients treated for cancer: A center’s 30-year experience. J Pediatr Hematol Oncol 2006;28(6):374–8.
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
16. Chan JY, Gooi Z, Mydlarz WK, Agrawal N. Risk of second primary malignancy after nasopharyngeal carcinoma in the United States: A population-based study. Head Neck 2016;38(Suppl 1):E1130–6.
17. Chen MC, Feng IJ, Lu CH, Chen CC, Lin JT, Huang SH, et al. The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: A population-based study in Taiwan over a 25-year period (1979–2003). Ann Oncol 2008;19(6):1180–6.
18. Scélo G, Boffetta P, Corbex M, Chia KS, Hemminki K, Friis S, et al. Second primary cancers in patients with nasopharyngeal carcinoma: A pooled analysis of 13 cancer registries. Cancer Causes Control 2007;18(3):269–78.
19. Lou J, Jiang L, Dai X, Wang H, Yang J, Guo L, et al. Radiation-induced sarcoma of the head and neck following radiotherapy for nasopharyngeal carcinoma: A single institutional experience and literature review. Front Oncol 2021;10:526360.
20. Scholz-Kreisel P, Kaatsch P, Spix C, Schmidberger H, Marron M, Grabow D, et al. Second malignancies following childhood cancer treatment in Germany from 1980 to 2014. Dtsch Arztebl Int 2018;115(23):385–92.
21. Marti JL, Jain KS, Morris LG. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. Thyroid 2015;25(6):681–7.
22. Arboleda LPA, de Mendonça RM, Lopez EE, Araújo AL, Palmier NR, de Pauli Paglioni M, et al. Global frequency and distribution of head and neck cancer in pediatrics, a systematic review. Crit Rev Oncol Hematol 2020;148:102892.
23. Liu C, Liao L, Wu G, Yan H, Chen X, Wang C, et al. Radiation- induced second primary squamous cell carcinoma of the oral cavity after radiotherapy for nasopharyngeal carcinoma. Oral Oncol 2020;109:104863.
24. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006;65(1):1–7.
25. International Commission on Radiological Protection. Recommendations. Ottawa, Canada: Annals of the ICRP Publication 60; 1990.
26. Chow JC, Au KH, Mang OW, Cheung KM, Ngan RK. Risk, pattern and survival impact of second primary tumors in patients with nasopharyngeal carcinoma following definitive intensity-modulated radiotherapy. Asia Pac J Clin Oncol 2019;15(1):48–55.
27. Kumar S. Second malignant neoplasms following radiotherapy. Int J Environ Res Public Health 2012;9(12):4744–59.
28. Altun M, Tambas M, Dagoglu N. Radiation Infield Second Tumors in Nasopharyngeal Carcinoma Patients. Abstract P2791, s523, ASTRO; 2014.